2025
Vascular segmental exclusion for recurrent vulvar squamous cell carcinoma invading the femoral vessels
Schwartz A, Azodi M, Cardella J, Chaar C. Vascular segmental exclusion for recurrent vulvar squamous cell carcinoma invading the femoral vessels. Journal Of Vascular Surgery Cases And Innovative Techniques 2025, 11: 101753. DOI: 10.1016/j.jvscit.2025.101753.Peer-Reviewed Original ResearchRecurrent vulvar squamous cell carcinomaVulvar squamous cell carcinomaInvasive vulvar carcinomaExtensive local invasionProgression of oncological diseasesSquamous cell carcinomaLower limb ischemiaSuperficial femoral arteryVulvar carcinomaFemoral artery embolismAbdomen-pelvisUnresectable tumorsArtery embolizationCell carcinomaLeft axillaryPopliteal artery bypassWide resectionThree-month follow-upLocal invasionArtery bypassComputed tomographyFollow-upNecrotic massLimb ischemiaFemoral vein
2024
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
Costa P, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Coelho P, Campoverde L, Hardy N, Bialick S, Freire A, D’Amato G, Chang Y, Mesenger J, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors. Cancer 2024, 131: e35647. PMID: 39543805, DOI: 10.1002/cncr.35647.Peer-Reviewed Original ResearchProgression-free survivalAnthracycline-containing regimensAnthracycline-based therapyDesmoid tumorsAdverse eventsOne-year progression-free survivalMulti-institutional retrospective analysisAnthracycline-containing regimenCommon grade 1Desmoid tumor patientsGrade 3 eventsAnthracycline-based chemotherapyHand-foot syndromeSecondary end pointsActivity of sorafenibProgressive desmoid tumorsYear of treatmentMedian TTRBaseline characteristicsTumor patientsLocal invasionTreatment responseSorafenibAnthracyclinesEnd points
2021
A Novel Treatment for Metastatic Serous Cystadenocarcinoma Using a Microwave Ablation: Case Report and Review of the Literature.
Murtha TD, Cornman-Homonoff J, Ayyagari R, Zhang X, Salem RR. A Novel Treatment for Metastatic Serous Cystadenocarcinoma Using a Microwave Ablation: Case Report and Review of the Literature. Pancreas 2021, 50: 434-440. PMID: 33835976, DOI: 10.1097/mpa.0000000000001785.Peer-Reviewed Case Reports and Technical NotesConceptsSerous cystadenocarcinomaSerous cystadenomaMicrowave ablationRecurrence 3 yearsSolitary hepatic metastasisEffective treatment optionPercutaneous microwave ablationPancreatic cystic neoplasmsRare malignant variantDistal pancreatectomyHepatic metastasesPatient factorsPercutaneous ablationCystic neoplasmsTreatment optionsCase reportMetastatic spreadMalignant variantAbdominal visceraLocal invasionNovel treatmentsCystadenomaHepatic implantsAdjacent structuresCystadenocarcinoma
2017
Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53
Kenny TC, Schmidt H, Adelson K, Hoshida Y, Koh AP, Shah N, Mandeli J, Ting J, Germain D. Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. Clinical Cancer Research 2017, 23: 5446-5459. PMID: 28630214, PMCID: PMC5600839, DOI: 10.1158/1078-0432.ccr-17-0342.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationCollagenDiagnostic ImagingDisease Models, AnimalDisease SusceptibilityExtracellular FluidFemaleGene Expression ProfilingHeterograftsHumansImmunohistochemistryMiceModels, BiologicalNeoplasm GradingNeoplasm InvasivenessRetrospective StudiesTumor Suppressor Protein p53ConceptsMammary glandBilateral mastectomy patientsInvasion scoreHigh-grade primary tumorsInterstitial fluidNormal mammary glandClin Cancer ResSporadic breast cancerBreast cancer cellsVisceral metastasesSpontaneous tumor formationClinical courseDuctal hyperplasiaResidual diseaseMastectomy patientsPrimary tumorDisease progressionRadiologic examinationBreast cancerLocal invasionMouse modelCollagen depositionMyofibroblast differentiationCancer ResExtracellular matrix
2012
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
Celià-Terrassa T, Meca-Cortés Ó, Mateo F, de Paz A, Rubio N, Arnal-Estapé A, Ell B, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano J, Estarás C, Ulloa C, ρlvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros A, Gomis R, Kang Y, Blanco J, Fernández P, Thomson T. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. Journal Of Clinical Investigation 2012, 122: 1849-1868. PMID: 22505459, PMCID: PMC3366719, DOI: 10.1172/jci59218.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, DifferentiationCadherinsCell Line, TumorCell MovementCell ShapeCoculture TechniquesEpithelial CellsEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Regulatory NetworksHomeodomain ProteinsHumansMaleMiceMice, Inbred NODMice, SCIDNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingNeoplasm TransplantationProstatic NeoplasmsRepressor ProteinsSnail Family Transcription FactorsSpheroids, CellularTranscription FactorsTwist-Related Protein 1Urinary Bladder NeoplasmsZinc Finger E-box-Binding Homeobox 1ConceptsEpithelial-mesenchymal transitionDistant metastasisSelf-renewalGene programTumor-initiating cellsEpithelial-mesenchymal transition programProstate cancer cellsIn vitro invasionPrimary implantation sitesHuman cellular modelsMetastatic populationBladder cancerTumor subpopulationsLocal invasionMesenchymal-likeEpithelial featuresMetastatic phenotypeNeoplastic cellsMalignant progressionImplantation sitesMesenchymal traitsEMT factorsCancer cellsMesenchymal genesIn vivo
1998
A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
Garabedian E, Humphrey P, Gordon J. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 15382-15387. PMID: 9860977, PMCID: PMC28051, DOI: 10.1073/pnas.95.26.15382.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstatic intraepithelial neoplasiaTransgenic mouse modelProstate cancerIntraepithelial neoplasiaMouse modelNeuroendocrine cellsHuman prostate cancerNeuroendocrine cell lineagesWeeks of ageNeuroendocrine differentiationSimian virus 40 T antigenLocal invasionMouse prostateCancerNeoplasiaProstateWeeksT antigenCell lineagesTransgene expressionMultiple pedigreesCellsMetastasisAndrogens
1996
Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?
Harrison L, Klimstra D, Brennan M. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Annals Of Surgery 1996, 224: 342-7; discussion 347-9. PMID: 8813262, PMCID: PMC1235378, DOI: 10.1097/00000658-199609000-00010.Peer-Reviewed Original ResearchConceptsPortal vein resectionMemorial Sloan-Kettering Cancer CenterPancreatic resectionPortal veinIsolated portal vein involvementPortal vein resection groupCancer CenterCurative pancreatic resectionIn-hospital mortality ratePortal vein involvementSurvival of patientsVein resectionCurative resectionMedian survivalVein involvementProspective databasePancreatic adenocarcinomaLocal invasionResectionAdenocarcinomaClinical involvementPatientsMortality ratePancreasControl group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply